REFERENCES
- Bush T., Helzlsouer K. Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial. Epidemiol. Rev. 1993; 15: 233–243, [PUBMED], [INFOTRIEVE], [CSA]
- Cavalli R., Caputo O., Gasco M. R. Solid lipid lipospheres of doxorubicin and idarubicin. Int. J. Pharm. 1993; 89: R9–R12, [CSA], [CROSSREF]
- Early Breast Cancer Trialists Collaborative Group. Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy. Lancet 1992; 339: 1–15, 339:71–85[CSA]
- Fisher B., Costantino J., Redmond C., Poisson R. R., Bowman D., Counture J., Dimitrov N., Wolmark N., Wickerham D., Fisher E., Margolese R., Robidoux A., Shibata H., Terz J., Paterson A., Feldma M., Farrar W., Evans J., Lickeley H., Ketner M. Randomized clinical trial evaluating tamoxifen in the treatment of patient with node-negative breast cancer who have oestrogen receptor positive tumors. N. Engl. J. Med. 1989; 320: 479–494, [PUBMED], [INFOTRIEVE], [CSA]
- Fornander T., Cedermark B., Mattsson A., Skoog L., Askergren J., Rutqvist L., Glas U., Silfverswäed C., Somell A., Wilking N., Hjalmar M. Adjuvant tamoxifen in early breast cancer occurrence of new primary cancers. Lancet 1989; I: 117–119, [CSA], [CROSSREF]
- Fundarò A., Cavalli R., Bargoni A., Vighetto D., Zara G. P., Gasco M. R. Non-stealth and stealth solid lipid nanospheres carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res. 2000; 42: 337–343, [CSA], [CROSSREF]
- Gao S., Singh J. In vitro percutaneous absorption enhancement of a lipophilic drug tamoxifen by terpenes. J. Control. Rel. 1998; 51: 193–199, [CSA], [CROSSREF]
- Gasco M. R. Solid lipid nanospheres from warm microemulsions. Pharm. Techonol. Eur. 1997; 9: 52–58, [CSA]
- Hansen M. B., Nielsen S. E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods 1989; 119: 203–210, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jaiyesimi I., Buzdar A., Decker D., Hortobagyi G. Use of tamoxifen for breast cancer: twenty-eight years later. J. Clin. Oncol. 1995; 13: 513–529, [PUBMED], [INFOTRIEVE], [CSA]
- Lim S. J., Kim C. K. Formulation parameters determining the physocochemical characteristics of solid lipid nanaoperticles loaded with all-trans retinoic acid. Int. J. Pharm. 2002; 243: 135–146, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Love R. Tamoxifen in auxiliary node-negative breast cancer: multisystem benefits and risks. Cancer Invest. 1992; 10: 587–593, [PUBMED], [INFOTRIEVE], [CSA]
- MacGregor J., Jorda V. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 1998; 50: 151–196, [PUBMED], [INFOTRIEVE], [CSA]
- Mehnert W., Mader K. Solid lipid nanoparticles. Production, characterization and applications. Adv. Drug Del. Rev. 2001; 47: 165–196, [CSA], [CROSSREF]
- Mosmann T. Rpid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983; 65: 55–63, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Mourits M. J. E., De Vries E. G. E., Willemse P. H. B., Ten Hoor K. A., Hollema H., Van Der Zee A. G. J. Tamoxifen treatment and gynecologic side effetcs: a review. Ostet. Gynecol. 2001; 97: 855–866, [CSA], [CROSSREF]
- Müller R. H., Heinemann S. Fat emulsions for parenteral nutrition I: evaluation of microscope and laser light scattering methods for the determination of the physical satbility. Clin. Nutr. 1992; 11: 223–272, [CSA], [CROSSREF]
- Müller R. H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur. J. Pharm. Bipharm. 2000; 50: 161–177, [CSA], [CROSSREF]
- Paterson S. C., Lim C. K., Smith K. D. Analysis of interaction between alpha-1-acid glycoprotein and tamoxifen and ist metabolites. Biomed. Chromatogr. 2003; 17: 143–148, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Schwarz C. Feste lipid nanopartkel: Herstellung, Charakterisienrung, Arzneistoffink und Freisetzung, Sterilisation und Lyophilisation. Ph.D. Thesis, Free University of Berlin. 1995
- Siekmann B., Westesen K. Investigation on solid lipid nanoparticles prepared by precipitazion in o/w emulsions. Eur. J. Pharm. Biopharm. 1996; 43: 104–109, [CSA]
- Weyhers H. Nanopartikel (SLN) fur die gewebsspezifische Arzneistofapplikation. Ph.D. Thesis, Free University of Berlin. 1995
- Yang S., Lu Y., Cai Y., Zhu J., Liang B., Yang C. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Rel. 1999; 59: 299–307, [CSA], [CROSSREF]
- Ziegler L., Budzar A. Current status of adjuvant therapy of early breast cancer. Am. J. Clin. Oncol. 1991; 14: 101–110, [PUBMED], [INFOTRIEVE], [CSA]
- Zur Muhlen A. Feste Lipid Nanopartikel mit prolongierter Wirkstoffliberation, Herstellung, Langzeitstabilitat, charakterisierung Freisetzungsverhalten und mechanismen. Ph.D. Thesis, Frei Universitat Berlin. 1996
- Zur Muhlen A., Schwarz C., Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery-drug release and release mechanism. Eur. Pharm. Biopharm. 1998; 45: 149–155, [CSA], [CROSSREF]